We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Cooper Companies (COO) Scales a New 52-Week High
Read MoreHide Full Article
Share price of The Cooper Companies (COO - Free Report) rallied to a new 52-week high of $182.21 on Jul 8, eventually closing a tad bit lower at $181.83. This represents a strong year-to-date return of approximately 35.5%, better than the S&P 500’s 4.2% over the same period.
Currently, Cooper Companies holds a Zacks Rank #2 (Buy). The stock has a market cap of $8.81 billion and a long-term expected earnings growth rate of 11.5%.
Growth Catalysts
Cooper Companies reported an impressive first quarter of 2016 with revenues of $483.8 million, improving 9% year over year at constant currency. Notably, adjusted earnings of $2.05 per share beat the Zacks Consensus Estimate by 13 cents, up 19% on a year-over-year basis.
Each and every segment of the company contributed toward the growth opportunities. The CooperVision segment (CVI) of the company posted a stellar performance, raking in revenues of $391.2 million (up 9% at constant currency). Particularly, the Silicone hydrogel line of products at the segment (Biofinity, Clariti, MyDay and Avaira) is considered a major growth contributor.
The CooperSurgical (CSI) unit of the company performed exceptionally well, enhancing the growth trajectory. Revenues at the segment surged 6% year over year at constant currency to $92.6 million.
Also, strategic tie-ups with the companies like Genesis Genetics, K-Systems and Recombine are fortifying the company’s position in the IVF global market, which should also open up newer avenues in the days ahead.
Meanwhile, encouraged by the stellar first-quarter performance, Cooper Companies raised its full-year 2016 guidance. The company now expects revenues in the range of $1.93–$1.96 billion while adjusted earnings are forecasted in the band of $8.20 to $8.50 per share.
Estimate Revisions
The Zacks Consensus Estimate for fiscal 2016 increased by 18 cents to $8.38 over the last 60 days. Similarly, fiscal 2017, estimates have scaled a massive 31 cents to $9.45 over the same time frame.
Other Key Picks
Other favorably ranked stocks in the broad medical sector include Halyard Health Inc , C.R. Bard Inc and Becton, Dickinson and Company (BDX - Free Report) . Notably, Halyard Health sports a Zacks Rank #1 (Strong Buy) while C.R. Bard and Becton, Dickinson carry a Zacks Rank #2.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Cooper Companies (COO) Scales a New 52-Week High
Share price of The Cooper Companies (COO - Free Report) rallied to a new 52-week high of $182.21 on Jul 8, eventually closing a tad bit lower at $181.83. This represents a strong year-to-date return of approximately 35.5%, better than the S&P 500’s 4.2% over the same period.
Currently, Cooper Companies holds a Zacks Rank #2 (Buy). The stock has a market cap of $8.81 billion and a long-term expected earnings growth rate of 11.5%.
Growth Catalysts
Cooper Companies reported an impressive first quarter of 2016 with revenues of $483.8 million, improving 9% year over year at constant currency. Notably, adjusted earnings of $2.05 per share beat the Zacks Consensus Estimate by 13 cents, up 19% on a year-over-year basis.
COOPER COS Price and Consensus
COOPER COS Price and Consensus | COOPER COS Quote
Each and every segment of the company contributed toward the growth opportunities. The CooperVision segment (CVI) of the company posted a stellar performance, raking in revenues of $391.2 million (up 9% at constant currency). Particularly, the Silicone hydrogel line of products at the segment (Biofinity, Clariti, MyDay and Avaira) is considered a major growth contributor.
The CooperSurgical (CSI) unit of the company performed exceptionally well, enhancing the growth trajectory. Revenues at the segment surged 6% year over year at constant currency to $92.6 million.
Also, strategic tie-ups with the companies like Genesis Genetics, K-Systems and Recombine are fortifying the company’s position in the IVF global market, which should also open up newer avenues in the days ahead.
Meanwhile, encouraged by the stellar first-quarter performance, Cooper Companies raised its full-year 2016 guidance. The company now expects revenues in the range of $1.93–$1.96 billion while adjusted earnings are forecasted in the band of $8.20 to $8.50 per share.
Estimate Revisions
The Zacks Consensus Estimate for fiscal 2016 increased by 18 cents to $8.38 over the last 60 days. Similarly, fiscal 2017, estimates have scaled a massive 31 cents to $9.45 over the same time frame.
Other Key Picks
Other favorably ranked stocks in the broad medical sector include Halyard Health Inc , C.R. Bard Inc and Becton, Dickinson and Company (BDX - Free Report) . Notably, Halyard Health sports a Zacks Rank #1 (Strong Buy) while C.R. Bard and Becton, Dickinson carry a Zacks Rank #2.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>